Significant progress on multiple fronts – obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement of NYSE American trading
Melanocortin-based therapies

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

PRNewswire

Palatin's obesity pipeline is advancing towards clinical trials in 2026.
Collaboration with Boehringer Ingelheim brings significant upfront and milestone payments.
Public offering closed, regaining NYSE compliance and enhancing cash position.
Melanocortin-based therapies show promise for rare obesity disorders.
Upcoming teleconference will update on operations and corporate progress.

Strategic combination positions combined company to capture AI infrastructure demand at scaleMovano (NASDAQ:MOVE) shareholders gain exposure to rapidly emerging AI infrastructure pure play platform with differentiated

MOVE

CORVEX TO GO PUBLIC IN ALL-STOCK MERGER WITH MOVANO, CREATING A PURE-PLAY PLATFORM FOR SECURE AI INFRASTRUCTURE AND HIGH-PERFORMANCE INFERENCE

Movano and Corvex announced a definitive merger agreement.
The merger aims to enhance AI infrastructure capabilities and efficiency.
Movano shareholders will benefit from a growing AI-focused platform.
Corvex raised $40 million, supporting the merger's financial framework.
Movano plans to market its medical devices, including the EvieMED Ring.


CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications


Acquisition aligns with

CDTX

Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

Business Wire

Merck is acquiring Cidara for $221.50 per share.
CD388 is a Phase 3 antiviral for influenza prevention.
Acquisition enhances Merck's respiratory portfolio.
CD388 received Breakthrough Therapy Designation from the FDA.
Transaction expected to close in Q1 2026.

Surmodics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/SRDX">SRDX</a>) ("Surmodics" or the "Company"), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States District Court for the Northern District of Illinois (the "District Court") has denied a request by the U.S. Federal Trade Commission (the "FTC") and certain state regulators to issue a preliminary injunction that would have prevented the Company and GTCR LLC ("GTCR") from consummating the proposed acquisition of the Company by an affiliate of GTCR (the "Merger").


Consummation of the Merger remains subject to a Temporary Restraining Order under which the parties to the Merger agree not to consummate the Merger prior to 5:00 p.m. Central time on Monday, November 17. It also remains subject to the satisfaction or waiver of closing conditions set forth in the agreement related to the Merger (the "merger agreement"), including (1) the absence of any injunction or other legal restraint or prohibition that would prevent or prohibit the consummation of the Merger, (2) the absence of a "Company Material Adverse Effect" (as defined in the merger agreement) with respect to the Company and (3) other customary closing conditions.


"The District Court's ruling is a significant step toward being able to complete the Merger, which we continue to believe will position the Company to continue to deliver compelling benefits for physicians, patients and customers going forward," said Gary Maharaj, President and CEO of Surmodics, Inc. "I would like to extend a heartfelt thanks to our legal advisors for their hard work in helping Surmodics to defend this proposed transaction in court, and to our employees for their unwavering dedication to maintaining our excellent operating performance."


About Surmodics, Inc.


Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company's expertise in proprietary surface modification and drug-delivery coating technologies, along with its device design, development, and manufacturing capabilities. The Company's mission is to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.surmodics.com&amp;esheet=54355865&amp;newsitemid=20251110939371&amp;lan=en-US&amp;anchor=www.surmodics.com&amp;index=1&amp;md5=3144bba18963157c65ca8c045423e1f4" shape="rect">www.surmodics.com</a>. The content of Surmodics' website is not part of this press release or part of any filings that the Company makes with the Securities and Exchange Commission (the "SEC").


Safe Harbor for Forward-Looking Statements


This press release contains forward-looking statements. Statements that are not historical or current facts, including statements regarding completion of the Merger, the Company's belief that the Merger will position the Company to continue to deliver compelling benefits for physicians, patients and customers, when the pending Merger will be consummated, if at all, and its potential consequences, including the expected financing of the Merger, the expectation that the Company will be privately held after the Merger, and conditions for consummation of the Merger, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including the factors identified under "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2024, and updated in our subsequent reports filed with the SEC. These reports are available in the Investors section of our website at <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsurmodics.gcs-web.com&amp;esheet=54355865&amp;newsitemid=20251110939371&amp;lan=en-US&amp;anchor=https%3A%2F%2Fsurmodics.gcs-web.com&amp;index=2&amp;md5=2ffc974e5c546bfa8bf945ecffd6a40f" shape="rect">https://surmodics.gcs-web.com</a> and at the SEC website at <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54355865&amp;newsitemid=20251110939371&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=57d2a8bf5bafe81c42741fa008140433" shape="rect">www.sec.gov</a>. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.

<img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251110939371r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20251110939371/en/" rel="nofollow">https://www.businesswire.com/news/home/20251110939371/en/</a>
Surmodics Investor Inquiries:
 Jack Powell, Investor Relations
 <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:ir@surmodics.com" shape="rect">ir@surmodics.com</a>


Surmodics Public Relations Inquiries:
 <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:pr@surmodics.com" shape="rect">pr@surmodics.com</a>


Surmodics, Inc. (NASDAQ:SRDX) (&#34;Surmodics&#34; or the &#34;Company&#34;), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States District Court

SRDX

Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR

District Court denied FTC's request to halt Surmodics and GTCR merger.
Merger completion requires no legal restraining orders or adverse effects.
CEO Gary Maharaj believes merger enhances benefits for stakeholders.
Merger has potential to change the company's operational landscape.
Surmodics specializes in medical technology and diagnostics.

GRAND RAPIDS, Mich., Nov. 11, 2025 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE:SI), a commercial-stage medical technology company exclusively focused on transforming the

Shoulder Innovations Reports Third Quarter 2025 Financial Results and Increases Full-Year Revenue Guidance

Shoulder Innovations reported $11.8 million revenue, up 58% YoY.
Sold 1,584 implant systems, a 53% increase compared to last year.
Gross margin for Q3 was 76.2%, down slightly from last year.
Increased full-year revenue guidance to $45-$46 million for 2025.
Phase I FDA clearance for new product line enhances growth potential.

Market Monitoring While You Sleep

Let AI Agent scan the market to help you spot opportunities and avoid losses — so you don't have to.

Trusted By Profesionals From

Get Signals, Not Noise

Read Less, Know More

Less Research, More Insights

What We Provide

What Ours Users Say

Powered By Premium Data Sources

Frequently Asked Questions